Program
olaparib
Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.
Drug pageOlaparib: every studyMany companies study it; this page follows only the 76 they lead. All 323 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 5915 open or running | phase 4since Jun 10, 2015 | Jun 27, 2007 | Apr 6, 2027phase 3 · NCT04421963 |
| Merck | 125 open or running | phase 3since Mar 29, 2018 | Aug 3, 2016 | May 5, 2027phase 3 · NCT04380636 |
| Novartisits history only | 20 open or running | phase 3since Jan 25, 2021 | Jan 25, 2021 | none ahead |
| Boryung Pharmaceuticalits history only | 11 open or running | phase 1since Jul 7, 2025 | Jul 7, 2025 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 1since Apr 7, 2024 | Apr 7, 2024 | none ahead |
| Daewoong Pharmaceuticalits history only | 11 open or running | phase 1since Jan 19, 2026 | Jan 19, 2026 | Mar 2027phase 1 · NCT07371104 |
Also a collaborator on its studies: Myriad Genetic Laboratories, Frontier Science & Technology Research Foundation, Hoffmann-La Roche, Myriad Genetics, Iqvia Pty, Covance, Theradex, Parexel and KuDOS Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2016First study: phase 2 study in Metastatic Castration-Resistant Prostate CancerFirst studyNCT02861573 · 1,200 enrolled
- Mar 29, 2018Phase 3 study in Hematologic NeoplasmsNCT03486873 · 3,500 planned · United States, Argentina, Australia and more
- Nov 12, 2018Phase 3 study in Ovarian NeoplasmsNCT03740165 · 1,367 enrolled · United States, Australia, Belgium and more
- Nov 14, 2018Phase 2 study in Advanced Solid NeoplasmsNCT03742895 · 329 enrolled · United States, Argentina, Australia and more
- Feb 6, 2019Phase 3 study in Prostatic NeoplasmsNCT03834519 · 793 enrolled · United States, Argentina, Australia and more
- Jun 3, 20192 phase 3 studies in CarcinomaNCT03976362, NCT03976323
- Oct 9, 2019Phase 2 study in Solid TumorsNCT04123366 · 333 enrolled · United States, Argentina, Australia and more
- Dec 5, 2019Phase 2 study in Triple Negative Breast NeoplasmsNCT04191135 · 462 enrolled · United States, Canada, Chile and more
- May 5, 2020Phase 3 study in Lung NeoplasmsNCT04380636 · 870 enrolled · United States, Argentina, Canada and more
- Jul 1, 2020Phase 3 study in Colorectal NeoplasmsNCT04456699 · 335 enrolled · United States, Australia, Belgium and more
- Nov 5, 2020Phase 3 study in Small Cell Lung CarcinomaNCT04624204 · 672 enrolled · United States, Australia, Belgium and more
Ahead
- May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsNCT04380636
- Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT02861573
- Oct 28, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT04624204
- Aug 4, 2043Primary completion: phase 3 study in Hematologic NeoplasmsNCT03486873
TargetBeta
“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule
Studies
All 12 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Oct 28, 2027 | 672 |
| NCT04456699Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Mar 27, 2023 | 335 |
| NCT04380636Lung Neoplasms · United States, Argentina, Canada and more | 3 | Active, not recruiting | May 5, 2027 | 870 |
| NCT04191135Triple Negative Breast Neoplasms · United States, Canada, Chile and more | 2 | Terminated | Dec 15, 2022 | 462 |
| NCT04123366Solid Tumors · United States, Argentina, Australia and more | 2 | Completed | Jun 8, 2026 | 333 |
| NCT03976362Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Sep 21, 2023 | 851 |
| NCT03976323Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Feb 7, 2024 | 1,003 |
| NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Mar 14, 2022 | 793 |
| NCT03742895Advanced Solid Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Aug 12, 2025 | 329 |
| NCT03740165Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Aug 26, 2024 | 1,367 |
| NCT03486873Hematologic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Aug 4, 2043 | 3,500 |
| NCT02861573Metastatic Castration-Resistant Prostate Cancer | 2 | Active, not recruiting | Oct 22, 2027 | 1,200 |
How it is read
Names in the registry
- “Olaparib”, 38 entries
- “olaparib”, 10 entries
- “AZD2281”, 10 entries
- “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
- “Olaparib 300mg tablets”, 3 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 24 studies
- Breast Neoplasms, 7 studies
- Prostatic Neoplasms, 7 studies
- Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.